Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Brepocitinib, a selective TYK2-JAK1 inhibitor, showed rapid, sustained skin disease control, itch relief, and improved quality of life in dermatomyositis patients over 52 weeks with an acceptable safety profile in a global phase 3 trial.
Elevated serum amyloid A correlates with rapidly progressive interstitial lung disease and mortality in dermatomyositis, with combined assessment alongside anti-MDA5 antibody improving risk stratification.
Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enablin